

BENJAMIN C. MIZER
Principal Deputy Assistant Attorney General
JONATHAN F. OLIN
Deputy Assistant Attorney General
Civil Division
U.S. Department of Justice
MICHAEL S. BLUME, Director
Consumer Protection Branch
KATHLEEN M. KONOPKA, Trial Attorney
Consumer Protection Branch
U.S. Department of Justice
PO Box 386
Washington, DC 20044-0386
(202) 514-1586 (phone)
(202) 514-8742 (fax)
kathleen.konopka@usdoj.gov
Attorneys for Plaintiff United States of America

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
SAN FRANCISCO DIVISION

UNITED STATES OF AMERICA,)
)
Plaintiff,)
)
v.)
)
KUN WO FOOD PRODUCTS, INC.,)
)
a corporation, and)
ZI XING LIU and ZI CHEN LIU,)
individuals,)
)
Defendants.)

Civil No. __16-1927__

COMPLAINT FOR INJUNCTION

Plaintiff, the United States of America, by its undersigned counsel, and on behalf of the
United States Food and Drug Administration (“FDA”), respectfully represents to this Court as
follows:

COMPLAINT FOR PERMANENT INJUNCTION

1 7. Defendant Zi Cheng Liu is a co-owner of Kun Wo. Mr. Zi Chen Liu shares
2 responsibility with Defendant Zi Xing Liu for the firm's production processes. He is also
3 responsible for product distribution. Defendant Zi Chen Liu performed his duties at 2939 16th
4 Street, San Francisco, California 94103, within the jurisdiction of this Court.

5 8. Defendants were engaged in preparing, processing, packing, holding, and
6 distributing articles of food, including ready-to-eat rice noodles.

7 9. Defendants' rice noodles were processed from ingredients, including rice, which
8 were shipped from locations outside the state of California, including Arkansas. Defendants
9 distributed their products within the state of California, to local customers in the San Francisco
10 area.

11 **DEFENDANTS' VIOLATIONS OF THE ACT**

12 10. Defendants violate the Act, 21 U.S.C. § 331(k), by causing food to become
13 adulterated while it is held for sale after shipment of one or more of its components in interstate
14 commerce.

15 11. Food is adulterated with the meaning of the Act if it has been prepared, packed,
16 or held under insanitary conditions whereby it may have become contaminated with filth, or
17 whereby it may have been rendered injurious to health. 21 U.S.C. § 342(a)(4).

18 12. Food processors must adhere to the current good manufacturing practices
19 ("cGMP") provided by FDA regulations. 21 C.F.R. pt. 110. The cGMP standards are applied in
20 determining whether food is adulterated under the Act. 21 C.F.R. § 110.5(a).

21 13. Defendants' rice noodles have been manufactured and distributed at room
temperature and intended to be consumed with little or no further processing. Thus, the manner

1 in which Defendants prepare, pack, hold, and distribute their rice noodles is crucial to minimize
2 the potential for bacterial contamination and reduce the risk of illness to consumers.

3 14. FDA inspections at Defendants' facility establish that Defendants repeatedly
4 violated the Act by failing to adhere to cGMP, preparing, packing, and holding rice noodles
5 under insanitary conditions whereby the noodles may have become contaminated with filth or
6 may have been rendered injurious to health, and failed to take corrective actions to come into
7 compliance, despite notification of their deficiencies by the FDA.

8 15. Defendants' rice noodles are at risk of contamination by several types of disease-
9 causing bacteria including *Listeria monocytogenes* ("L. mono"), *Bacillus cereus* ("B. cereus"),
10 *Salmonella*, *Echerichia coli* ("E. coli"), and *Staphylococcus aureus* ("S. aureus").

11 16. Defendants' rice noodles are adulterated within the meaning of 21 U.S.C. §
12 342(a)(4), and Defendants' violations are likely to recur absent court action.

13 **FDA INSPECTIONS**

14 17. FDA conducted its most recent inspection of Defendants' facility on January 20-
15 21, and February 4, 2016 ("the 2016 inspection"). This inspection followed a previous violative
16 inspection in September and October 2015 ("the 2015 inspection").

17 18. The 2016 inspection documented significant evidence of Defendants' failure to
18 follow cGMP, practices that cause food to be at risk of bacterial contamination, and Defendants'
19 failure to correct violations found in the 2015 inspection, including but not limited to the
20 following:

21 (a) Defendants failed to take all necessary precautions to prevent food handlers from
contaminating food with microorganisms or foreign material, as required by 21 C.F.R.
§ 110.10(b)(9). For example, an employee used the vat containing rice soaking for the day's

1 production to rinse her bare hands after handling equipment and touching her face and hair.

2 Employees also touched packing boxes, electrical switches, a fuse box, buckets, carts, and
3 machinery, all of which were soiled, and then touched rice noodles without sanitizing or
4 changing their gloves;

5 (b) Defendants failed to take all reasonable precautions throughout food
6 manufacturing operations to ensure that production procedures do not contribute contamination
7 from any source, as required by 21 C.F.R. § 110.80. For example, condensate dripped from a
8 hose suspended from the ceiling into the vat containing soaking rice and from a copper pipe with
9 a green and black film on its surface into a grinder containing rice for processing;

10 (c) Defendants failed to handle and maintain equipment, containers, and utensils used
11 to convey, hold, or store food in a manner that protects food from contamination, as required by
12 21 C.F.R. § 110.80(b)(7). For example, the machines used to steam, cool, slice, and weigh the
13 rice noodles were covered in grease and grime. FDA investigators observed that the first sheets
14 of rice noodles coming off the production machine contained particulate matter.

15 Additionally, a black mold-like substance was observed on the mesh surface of colanders used to
16 scoop rice from the soaking vat;

17 (d) Defendants failed to take effective measures to exclude pests from processing
18 areas and protect against contamination of food by pests, as required by 21 C.F.R. § 110.35(c).
19 For example, the top and bottom of the front door and back screen door of the facility had gaps
20 that were large enough to permit pests to enter the premises and access the raw-material storage
21 area and the food-processing area, and raw ingredients and recycled boxes were stored in the
front of the facility in a disorganized, cluttered manner that may attract and harbor pests;

(e) Defendants failed to hold food in a manner to prevent its contamination with

1 bacteria, as required by 21 C.F.R. § 110.8(b)(3), by maintaining its finished rice noodles at room
2 temperature for many hours;

3 (f) Defendants failed to maintain buildings, fixtures, and other physical facilities in a
4 sanitary condition, and failed to clean equipment in a manner that prevents contamination of
5 food and food-contact surfaces, as required by 21 C.F.R. § 110.35(a). For example, employees
6 used a hose to spray the floor and machinery with water that splashed around the soaking vat and
7 grinders and near processing tables. Water pooled on the floor and remained wet after cleaning
8 was completed. The uneven floor tiles near the vat, grinders, and mixer, used to process the rice
9 and other ingredients into rice slurry, also caused water to pool and prevented it from draining.
Uncovered food was stored in close proximity to locations where water pooled and splashed; and

10 (g) Defendants failed to minimize the potential for contamination of food and food-
11 contact surfaces when operating fans, as required by 21 C.F.R. § 110.20(b)(6). For example,
12 sheets of rice noodles were cooled by fans covered in dirt and debris that blew air directly on the
food.

13 19. FDA documented the same or similar violations during the 2015 inspection,
14 including, but not limited to:

15 (a) employees using the vat containing soaking rice to rinse their bare hands, rags, and
16 buckets after using the rags and buckets to clean the production area with detergent, and
17 employees touching dirty equipment and then using their bare, unwashed hands to grab rice
noodles for packaging;

18 (b) condensate dripping off a hose, covered in dirt and black residue, onto the rim of an
19 uncovered grinder filled with an in-process rice slurry;

1 (c) employees submerging soiled buckets from the floor into the vat of soaking rice to fill
2 them with water, which was then splashed onto the floor within one foot of trays of finished
3 product;

4 (d) cockroaches and fruit flies in the food processing area and a rodent in the area where
5 raw ingredients were stored;

6 (e) the conveyor belts on a machine used to steam, cool, and slice rice noodles covered
7 with a build-up of brown residue and the first sheets of rice noodles coming off the machine
8 containing particulate matter;

9 (f) finished, cut rice noodles held in buckets with dirt on their outsides and built-up
10 grease on their rims. Employees packaged the rice noodles that touched the soiled rims and
11 outsides of the buckets, as well as noodles that came off the slicing machine's soiled conveyor
12 belt, missed the buckets, and landed on a tray underneath the equipment;

13 (g) an employee using a soiled hose from the floor to flush rice slurry from the grinder
14 and from the mixer hose, which transports the slurry from the grinder to the mixer; and

15 (h) sheets of rice noodles being cooled by fans covered in dirt and debris that blew air
16 directly on the food.

17 20. During the 2015 inspection, FDA investigators swabbed various surfaces in
18 Defendants' production area, including the buckets used during processing. FDA's analyses of
19 these samples revealed the presence of bacterial contamination at the facility. *L. mono* was
20 identified on the exterior of one bucket, and *L. seeligeri* was found on the exterior of another
21 bucket. *L. mono* is the bacterium that causes the disease listeriosis. The most serious forms of
listeriosis can cause meningitis and septicemia. *L. seeligeri* does not cause disease; however, it
is a marker indicating that conditions are favorable for the survival and growth of *L. mono*. FDA

1 investigators noted during the 2015 inspection that Defendants' employees routinely submerged
2 these buckets in the water that contained soaking rice. *L. mono* was found elsewhere in the
3 environment, for example, on a brick supporting one corner of the soaking vat, on a drain, and on
4 a cracked floor tile. Defendants' employees splashed or sprayed water on or near these areas,
5 which were in close proximity to uncovered food.

NOTIFICATIONS OF NON-COMPLIANCE

6 21. At the close of the 2015 and 2016 inspections, FDA investigators provided a List
7 of Inspectional Observations ("Form FDA-483") to Defendants enumerating the observed
8 violations. An investigator also discussed the violations in Cantonese with Defendants to ensure
9 that they understood the deficiencies and the importance of corrections.

10 22. FDA also notified Defendant Zi Xing (David) Liu of the positive *L. mono* test
11 results by telephone on October 29, 2015.

12 23. In response to the 2015 inspection, Defendants made a number of inadequate and
13 unsuccessful corrections. Defendants replaced plastic buckets used for packing rice noodles and
14 fans that cooled sheets of rice noodles, and removed the plastic bins of dirty rags that were stored
15 above uncovered finished product. Defendants also promised to institute policies to improve
16 employees' practices, including posting signs that the water in the vat used for soaking rice
17 should not be used to rinse employees' hands, buckets, rags, or sponges. However, the 2016
18 inspection revealed that the new buckets and fans had not been kept clean, and that employee
19 practices had not improved.

20 24. Despite FDA's efforts and warnings, and the Defendants' promises to correct
21 violations, Defendants have failed to comply with cGMP and implement controls that are

adequate to protect their food from the risk of contamination with filth and disease-causing bacteria.

25. Based on the foregoing, there is a reasonable likelihood that, unless restrained by order of this Court, Defendants' violations will continue in the manner set forth above.

WHEREFORE, the United States respectfully requests that the Court:

I. Order that Defendants, and each and all of their directors, officers, agents, representatives, employees, attorneys, successors, and assigns, and any and all persons in active concert or participation with any of them (including individuals, partnerships, corporations, subsidiaries, and affiliates), are permanently restrained and enjoined under 21 U.S.C. § 332(a) from directly or indirectly violating 21 U.S.C. § 331(k), by causing articles of food that are held for sale after shipment of one or more components in interstate commerce to become adulterated within the meaning of 21 U.S.C. § 342(a)(4);

II. Order that Defendants, and each and all of their directors, officers, agents, representatives, employees, attorneys, successors, and assigns, and any and all persons in active concert or participation with any of them (including individuals, partnerships, corporations, subsidiaries, and affiliates), cease, directly or indirectly, receiving, preparing, processing, packing, labeling, holding, or distributing articles of food unless and until Defendants bring their receiving, preparing, processing, packing, labeling, holding, and distribution operations into compliance with the Act and implementing regulations, to FDA's satisfaction;

III. Order that FDA be authorized pursuant to this injunction to inspect Defendants' place(s) of business and all records relating to the receiving, preparing, processing, packing, labeling, holding, and distribution of food to ensure continuing compliance with the terms of the

1 injunction, the costs of such inspections to be borne by Defendants at the rates prevailing at the
2 time the inspections are accomplished; and

3 IV. Award the United States its costs incurred in pursuing this action, including the costs
4 of investigation to date, and such other relief as the Court deems just and proper.

5 //

6 //

7 //

8 //

9 //

10 //

11 //

12 //

13 //

14 //

15 //

16 //

17 //

18 //

19 //

20 //

21 //

1 DATED this 12th day of April, 2016.

2 Respectfully submitted,

3 BENJAMIN C. MIZER
Principal Deputy Assistant Attorney General

4 JONATHAN F. OLIN
Deputy Assistant Attorney General

5 MICHAEL S. BLUME
6 Director

7 By: s/Kathleen M. Konopka
Kathleen M. Konopka
8 Trial Attorney
Consumer Protection Branch
9 Department of Justice, Civil Division
P.O. Box 386
10 Washington, D.C. 20044
Tel.: (202) 514-1586 (phone)
Fax.: (202) 514-8742 (fax)
11 kathleen.konopka@usdoj.gov

12 OF COUNSEL:

13 WILLIAM B. SCHULTZ
General Counsel

14 ELIZABETH H. DICKINSON
Chief Counsel
15 Food and Drug Division

16 ANNAMARIE KEMPIC
Deputy Chief Counsel for Litigation

17 CLAUDIA J. ZUCKERMAN
Senior Counsel
18 Office of the Chief Counsel
Food and Drug Administration
10903 New Hampshire Avenue
19 Bldg. 31, Room 4550
Silver Spring, MD 20993-0002
20 (301) 796-8609